54189-82-1

Basic information

• Product Name: 6-CHLORO-N-METHYL-NICOTINAMIDE
• Synonyms: 6-CHLORO-N-METHYL-NICOTINAMIDE;6-chloro-nicotinic acid N-MethylaMide
• CAS NO: 54189-82-1
• Molecular Formula: C₇H₇ClN₂O
• Molecular Weight: 170.59628
• Mol File: 54189-82-1.mol
• Article Data: 14

Chemical Properties

• Melting Point: 152.8-153.4 °C(Solv: dichloromethane (75-09-2))
• Boiling Point: 347.593 °C at 760 mmHg
• Flash Point: 164.019 °C
• Appearance: /
• Density: 1.264 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.548
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 13.85±0.46(Predicted)
• CAS DataBase Reference: 6-CHLORO-N-METHYL-NICOTINAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-CHLORO-N-METHYL-NICOTINAMIDE(54189-82-1)
• EPA Substance Registry System: 6-CHLORO-N-METHYL-NICOTINAMIDE(54189-82-1)

Safety Data

• Hazardous Substances Data: 54189-82-1(Hazardous Substances Data)

Usage

General Description

6-CHLORO-N-METHYL-NICOTINAMIDE is a chemical compound that belongs to the class of nicotinamide derivatives. It is an organic compound with the molecular formula C7H7ClN2O, consisting of a nicotinamide ring with a chlorine atom and a methyl group attached to it. 6-CHLORO-N-METHYL-NICOTINAMIDE is often used as a building block in organic synthesis and pharmaceutical research. It has potential applications in the development of new drugs and other biologically active compounds. Additionally, it may also have uses in the field of agrochemicals and crop protection.

InChI:InChI=1/C7H7ClN2O/c1-9-7(11)5-2-3-6(8)10-4-5/h2-4H,1H3,(H,9,11)

Upstream product

• 58757-38-3 6-Chloronicotinoyl chloride 
• 593-51-1 methylamine hydrochloride 
• 5326-23-8 6-Chloro-3-pyridinecarboxylic acid 
• 74-89-5 methylamine 
• 73781-91-6 6-Chloronicotinic acid methyl ester 

Downstream Products

• 720690-73-3 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl-3-pyridinecarboxamide 

Relevant articles and documents

Design and discovery of thioether and nicotinamide containing sorafenib analogues as multikinase inhibitors targeting B-Raf, B-RafV600E and VEGFR-2

New sorafenib derivatives containing thioether and nicotinamide moiety were designed and synthesized as B-Raf, B-RafV600E and VEGFR-2 multikinase inhibitors. Their in vitro enzymatic inhibitory activities against B-Raf, B-RafV600E and VEGFR-2 and their antiproliferative activities against HCT-116 and B16BL6 cell lines were evaluated and described. Most of the compounds showed potent activities against both cell lines and specific kinases. Compounds a1, b1 and c4, which exhibited the most potent inhibitory activities against B-Raf with IC50 of 21 nM, 27 nM and 17 nM, B-RafV600E with IC50 of 29 nM, 28 nM and 16 nM, VEGFR-2 with IC50 of 84 nM, 46 nM and 63 nM, respectively, and good antiproliferative activities, also demonstrated competitive antiangiogenic activities to sorafenib in in vitro HUVEC tube formation assay.

Design, synthesis and biological evaluation of thiourea and nicotinamide-containing sorafenib analogs as antitumor agents

A series of thiourea and nicotinamide-containing sorafenib analogs (7a-n) were designed and synthesized and their antiproliferative activities were tested against HCT116, MDA-MB-231, PC-3 and HepG2 cell lines. Most of the compounds showed potent activities against the four cell lines, compound 7h showed better activities than sorafenib against all four cell lines, and compounds 7a and 7e showed better activities against HCT116 and MDA-MB-231 cell lines. The anti-angiogenic activities of 7e and 7h were also better than that of sorafenib in both in vitro HUVEC tube formation assay and ex vivo rat thoracic aorta ring assay.

CARBINOL DERIVATIVES HAVING HETEROCYCLIC LINKER

[Object] It is to provide a novel LXRβ agonist useful as a preventative and/or therapeutic agent for atherosclerosis; arteriosclerosis such as those resulting from diabetes; dyslipidemia; hypercholesterolemia; lipid-related diseases; inflammatory diseases that are caused by inflammatory cytokines; skin diseases such as allergic skin diseases; diabetes; or Alzheimer's disease. [Solving Means] A carbinol compound represented by the following general formula (I) or salt thereof, or their solvate: (wherein, each V and W independently show N or C—R7; each X and Y independently show CH2, C═O, SO2, etc; Z shows CH or N; each R1, R2 and R7 independently show a hydrogen atom, C1-8 alkyl group, etc.; R3 shows C1-8 alkyl group; R4 shows an optionally substituted C6-10 aryl group or an optionally substituted 5- to 11-membered heterocyclic group; R5 and R6 show a hydrogen atom, etc.; L shows a C1-8 alkyl chain optionally substituted with an oxo group, etc.; and n shows any integer of 0 to 2.)